Azithromycin extended release vs amoxicillin/clavulanate: symptom resolution in acute sinusitis

Bradley F. Marple, Craig S. Roberts, Jennifer R. Frytak, Vernon F. Schabert, Jessica C. Wegner, Helen Bhattacharyya, Jay F. Piccirillo, Sonia P. Sanchez

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objective: The aim of the study was to compare early symptom resolution with a single 2-g dose of azithromycin extended release or 10 days of amoxicillin/clavulanate 875 mg/125 mg every 12 hours in patients with acute sinusitis. Materials and methods: This was a prospective, randomized, open-label, observational study to mimic "real-world" conditions, including patients with symptoms of acute bacterial sinusitis lasting between 7 and 30 days. Key symptoms were assessed twice daily by patient diary, and patients were interviewed by telephone at 12 and 28 days. The primary end point was symptom resolution at 5 days, defined as reporting "no problem" with at least 3 of 4 diary symptoms in 2 consecutive measures in the per-protocol population. Secondary end points included additional antibiotic use, sinusitis-related quality of life, and treatment satisfaction. Results: Three hundred seventy-eight patients were randomized to a single dose of azithromycin extended release and 371 to 10 days of amoxicillin/clavulanate. In the per-protocol population at day 5, 70/236 patients (29.7%) in the azithromycin extended release arm and 45/238 patients (18.9%) in the amoxicillin/clavulanate arm had resolution of symptoms (difference = 10.8%; 95% confidence interval [CI], 3.1-18.4%). By day 28, 26/236 patients (11.0%) in the azithromycin extended release arm and 27/238 patients (11.3%) in the amoxicillin/clavulanate arm had used additional antibiotics (difference = -0.4%; 95% CI: -6.1% to 5.3%). Additional physician visits, quality of life, and overall satisfaction were similar between groups. Conclusions: More patients randomized to azithromycin extended release experienced symptom resolution at day 5 than those randomized to amoxicillin/clavulanate, without experiencing differences in second antibiotic use at 28 days.

Original languageEnglish (US)
Pages (from-to)1-8
Number of pages8
JournalAmerican Journal of Otolaryngology - Head and Neck Medicine and Surgery
Volume31
Issue number1
DOIs
StatePublished - Jan 2010

Fingerprint

Clavulanic Acid
Azithromycin
Sinusitis
Amoxicillin
Anti-Bacterial Agents
Quality of Life
Confidence Intervals
Telephone
Population
Observational Studies
Physicians

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Azithromycin extended release vs amoxicillin/clavulanate : symptom resolution in acute sinusitis. / Marple, Bradley F.; Roberts, Craig S.; Frytak, Jennifer R.; Schabert, Vernon F.; Wegner, Jessica C.; Bhattacharyya, Helen; Piccirillo, Jay F.; Sanchez, Sonia P.

In: American Journal of Otolaryngology - Head and Neck Medicine and Surgery, Vol. 31, No. 1, 01.2010, p. 1-8.

Research output: Contribution to journalArticle

Marple, Bradley F. ; Roberts, Craig S. ; Frytak, Jennifer R. ; Schabert, Vernon F. ; Wegner, Jessica C. ; Bhattacharyya, Helen ; Piccirillo, Jay F. ; Sanchez, Sonia P. / Azithromycin extended release vs amoxicillin/clavulanate : symptom resolution in acute sinusitis. In: American Journal of Otolaryngology - Head and Neck Medicine and Surgery. 2010 ; Vol. 31, No. 1. pp. 1-8.
@article{d65bfde956654a79aaec794d81084860,
title = "Azithromycin extended release vs amoxicillin/clavulanate: symptom resolution in acute sinusitis",
abstract = "Objective: The aim of the study was to compare early symptom resolution with a single 2-g dose of azithromycin extended release or 10 days of amoxicillin/clavulanate 875 mg/125 mg every 12 hours in patients with acute sinusitis. Materials and methods: This was a prospective, randomized, open-label, observational study to mimic {"}real-world{"} conditions, including patients with symptoms of acute bacterial sinusitis lasting between 7 and 30 days. Key symptoms were assessed twice daily by patient diary, and patients were interviewed by telephone at 12 and 28 days. The primary end point was symptom resolution at 5 days, defined as reporting {"}no problem{"} with at least 3 of 4 diary symptoms in 2 consecutive measures in the per-protocol population. Secondary end points included additional antibiotic use, sinusitis-related quality of life, and treatment satisfaction. Results: Three hundred seventy-eight patients were randomized to a single dose of azithromycin extended release and 371 to 10 days of amoxicillin/clavulanate. In the per-protocol population at day 5, 70/236 patients (29.7{\%}) in the azithromycin extended release arm and 45/238 patients (18.9{\%}) in the amoxicillin/clavulanate arm had resolution of symptoms (difference = 10.8{\%}; 95{\%} confidence interval [CI], 3.1-18.4{\%}). By day 28, 26/236 patients (11.0{\%}) in the azithromycin extended release arm and 27/238 patients (11.3{\%}) in the amoxicillin/clavulanate arm had used additional antibiotics (difference = -0.4{\%}; 95{\%} CI: -6.1{\%} to 5.3{\%}). Additional physician visits, quality of life, and overall satisfaction were similar between groups. Conclusions: More patients randomized to azithromycin extended release experienced symptom resolution at day 5 than those randomized to amoxicillin/clavulanate, without experiencing differences in second antibiotic use at 28 days.",
author = "Marple, {Bradley F.} and Roberts, {Craig S.} and Frytak, {Jennifer R.} and Schabert, {Vernon F.} and Wegner, {Jessica C.} and Helen Bhattacharyya and Piccirillo, {Jay F.} and Sanchez, {Sonia P.}",
year = "2010",
month = "1",
doi = "10.1016/j.amjoto.2008.08.011",
language = "English (US)",
volume = "31",
pages = "1--8",
journal = "American Journal of Otolaryngology - Head and Neck Medicine and Surgery",
issn = "0196-0709",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Azithromycin extended release vs amoxicillin/clavulanate

T2 - symptom resolution in acute sinusitis

AU - Marple, Bradley F.

AU - Roberts, Craig S.

AU - Frytak, Jennifer R.

AU - Schabert, Vernon F.

AU - Wegner, Jessica C.

AU - Bhattacharyya, Helen

AU - Piccirillo, Jay F.

AU - Sanchez, Sonia P.

PY - 2010/1

Y1 - 2010/1

N2 - Objective: The aim of the study was to compare early symptom resolution with a single 2-g dose of azithromycin extended release or 10 days of amoxicillin/clavulanate 875 mg/125 mg every 12 hours in patients with acute sinusitis. Materials and methods: This was a prospective, randomized, open-label, observational study to mimic "real-world" conditions, including patients with symptoms of acute bacterial sinusitis lasting between 7 and 30 days. Key symptoms were assessed twice daily by patient diary, and patients were interviewed by telephone at 12 and 28 days. The primary end point was symptom resolution at 5 days, defined as reporting "no problem" with at least 3 of 4 diary symptoms in 2 consecutive measures in the per-protocol population. Secondary end points included additional antibiotic use, sinusitis-related quality of life, and treatment satisfaction. Results: Three hundred seventy-eight patients were randomized to a single dose of azithromycin extended release and 371 to 10 days of amoxicillin/clavulanate. In the per-protocol population at day 5, 70/236 patients (29.7%) in the azithromycin extended release arm and 45/238 patients (18.9%) in the amoxicillin/clavulanate arm had resolution of symptoms (difference = 10.8%; 95% confidence interval [CI], 3.1-18.4%). By day 28, 26/236 patients (11.0%) in the azithromycin extended release arm and 27/238 patients (11.3%) in the amoxicillin/clavulanate arm had used additional antibiotics (difference = -0.4%; 95% CI: -6.1% to 5.3%). Additional physician visits, quality of life, and overall satisfaction were similar between groups. Conclusions: More patients randomized to azithromycin extended release experienced symptom resolution at day 5 than those randomized to amoxicillin/clavulanate, without experiencing differences in second antibiotic use at 28 days.

AB - Objective: The aim of the study was to compare early symptom resolution with a single 2-g dose of azithromycin extended release or 10 days of amoxicillin/clavulanate 875 mg/125 mg every 12 hours in patients with acute sinusitis. Materials and methods: This was a prospective, randomized, open-label, observational study to mimic "real-world" conditions, including patients with symptoms of acute bacterial sinusitis lasting between 7 and 30 days. Key symptoms were assessed twice daily by patient diary, and patients were interviewed by telephone at 12 and 28 days. The primary end point was symptom resolution at 5 days, defined as reporting "no problem" with at least 3 of 4 diary symptoms in 2 consecutive measures in the per-protocol population. Secondary end points included additional antibiotic use, sinusitis-related quality of life, and treatment satisfaction. Results: Three hundred seventy-eight patients were randomized to a single dose of azithromycin extended release and 371 to 10 days of amoxicillin/clavulanate. In the per-protocol population at day 5, 70/236 patients (29.7%) in the azithromycin extended release arm and 45/238 patients (18.9%) in the amoxicillin/clavulanate arm had resolution of symptoms (difference = 10.8%; 95% confidence interval [CI], 3.1-18.4%). By day 28, 26/236 patients (11.0%) in the azithromycin extended release arm and 27/238 patients (11.3%) in the amoxicillin/clavulanate arm had used additional antibiotics (difference = -0.4%; 95% CI: -6.1% to 5.3%). Additional physician visits, quality of life, and overall satisfaction were similar between groups. Conclusions: More patients randomized to azithromycin extended release experienced symptom resolution at day 5 than those randomized to amoxicillin/clavulanate, without experiencing differences in second antibiotic use at 28 days.

UR - http://www.scopus.com/inward/record.url?scp=71849115228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71849115228&partnerID=8YFLogxK

U2 - 10.1016/j.amjoto.2008.08.011

DO - 10.1016/j.amjoto.2008.08.011

M3 - Article

C2 - 19944891

AN - SCOPUS:71849115228

VL - 31

SP - 1

EP - 8

JO - American Journal of Otolaryngology - Head and Neck Medicine and Surgery

JF - American Journal of Otolaryngology - Head and Neck Medicine and Surgery

SN - 0196-0709

IS - 1

ER -